Nathalie Cartier Lacave
About Nathalie Cartier Lacave
Nathalie Cartier Lacave serves as the VP of Neurobiology, CNS Sector Lead, and AskBio Paris Site Head at Asklepios BioPharmaceutical, Inc. since 2022, focusing on advancements in neurobiology and gene therapy.
Work at Asklepios BioPharmaceutical
Nathalie Cartier Lacave serves as the Vice President of Neurobiology and CNS Sector Lead at Asklepios BioPharmaceutical, Inc. (AskBio). She has been in this role since 2022, overseeing operations at the AskBio Paris site. Her responsibilities include leading initiatives related to neurobiology and managing projects within the central nervous system (CNS) sector. She is based at the Paris Brain Institute, located at Hôpital Pitié-Salpêtrière, where she contributes to advancing research and development in gene therapies.
Education and Expertise
Nathalie Cartier Lacave has a strong background in neurobiology, with extensive experience in the field of gene therapy. Her expertise encompasses various aspects of CNS disorders, particularly focusing on therapeutic approaches for conditions such as Huntington’s disease and spinocerebellar ataxias. Her academic and professional journey has equipped her with the knowledge and skills necessary to lead significant research initiatives in neurobiology.
Background
Nathalie Cartier Lacave has been actively involved in the scientific community, particularly in the area of CNS therapeutics. She has presented her research at notable conferences, including the East Coast CNS Therapeutics Xchange in 2021. Her participation in these events highlights her commitment to sharing knowledge and advancements in the field of neurobiology.
Achievements
Nathalie Cartier Lacave has received recognition for her contributions to the field of neurobiology, including being honored with the Ann B. Moser Award. This accolade reflects her dedication and impact within the scientific community, particularly in the development of gene therapies for neurological disorders. Additionally, she has presented at the RE(ACT) Congress & IRDiRC Conference, focusing on gene therapy applications for Huntington’s disease and spinocerebellar ataxias.